Who can enter
- Children and adolescents with the clinical suspicion of an invasive fungal infection in their lungs
- Age: 5-18 years old
Goal
The goal of this study is to examine the accuracy of exhaled breath analysis in the early diagnosis of a pulmonary invasive infection in immunocompromised children.
Background
Diagnosis of an invasive pulmonary fungal infection in clinical practice is difficult, due to unspecific clinical signs and symptoms of the fungal infection. Furthermore, these patients are sometimes severely ill, and are not always able to undergo an invasive diagnostic procedure. However, to prove diagnosis an invasive diagnostic procedure is necessary. Exhaled breath as a non-invasive diagnostic technique may be an alternative option.
Study details
Official title
Exhaled Breath as Diagnostic Approach for Invasive Pulmonary Aspergillosis in Immunocompromised Pediatric Patients
Cancer type
All cancer types
Phase
Pilot study
Maximum number of patients
5 children with the diagnosis of probable or proven pulmonary fungal infection
Start date
March 2022
Status
Open
Local principal investigator
Dr. C.L. Lindemans/drs. L. Rotte
Sponsor
Princess Maxima Center for pediatric oncology
Approval
The study of this new diagnostic test has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO and Government of the Netherlands.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
February 3, 2025
